Regitrat
Antineoplastic, EGFR tyrosine kinase inhibitor. Indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations (Del19, L858R, and other less common mutations).
Therapeutic Area
Antineoplastic + Oncohematology + Protein Kinase Inhibitor
Active Ingredient
Bosutinib
Line
Hematology + Oncology
Dosage Forms
100 mg x 28 coated tablets
400 mg x 28 coated tablets
500 mg x 28 coated tablets
